

Ref no: 251310817  
From: Public  
Date: 31/08/17  
Subject: Biologics and biosimilar prescribing

## REQUEST & RESPONSE

I have a Freedom of Information request regarding biologics and biosimilar prescribing. Could you please provide me with the following numbers of patients treated in the last 12 months [latest 12 months possible] with the following drugs regardless of disease?

Pharmacy response:

Data JAC Crystal Report; Distinct count of patients dispensed between 1<sup>st</sup> August 2016 and 1<sup>st</sup> September 2017:

Number of patients treated	All Patients
TOTAL	1305
Abatacept [Orencia]	21
Adalimumab [Humira]	262
Apremilast [Otezla]	16
Baricitinib [Olumiant]	
Certolizumab [Cimzia]	20
Etanercept [Enbrel]	117
Etanercept Biosimilar [Benepali or Erelzi]	76
Golimumab [Simponi]	44
Infliximab [Remicade]	18
Infliximab Biosimilar [Inflectra, Remsima or Flixabi]	220
Rituximab [Mabthera]	373
Rituximab Biosimilar [Rixathon or Truxima]	
Secukinumab [Cosentyx]	5

Tocilizumab [Ro Actemra]	93
Tofacitinib [Xeljanz]	
Ustekinumab [Stelara]	23
Vedolizumab [Entyvio]	17
Ixekizumab [Taltz]	